To assess reactogenicity and immunogenicity of GSK Biologicals' 10-valent pneumococcal conjugate vaccine, when co-administered with GSK Biologicals' DTPa-HBV-IPV/Hib vaccine (Infanrix Hexa) at 2, 4 and 6 months of age.

Trial Profile

To assess reactogenicity and immunogenicity of GSK Biologicals' 10-valent pneumococcal conjugate vaccine, when co-administered with GSK Biologicals' DTPa-HBV-IPV/Hib vaccine (Infanrix Hexa) at 2, 4 and 6 months of age.

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Oct 2016

At a glance

  • Drugs Pneumococcal 10-valent vaccine conjugate (Primary)
  • Indications Otitis media; Pneumococcal infections; Pneumonia
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 21 Dec 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top